EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Parthenolide: pioneering new frontiers in hematological malignancies

Elmira Zarei, Ayda Zarei, Azadeh Omidkhoda

Frontiers in Pharmacology · 15.04.2025 · 16

DOI: 10.3389/fphar.2025.1534686 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.04.2025. Verfasst von Elmira Zarei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Blood Banking, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematological malignancies are the fifth most prevalent cancer category in developed countries, presenting significant treatment challenges. The side effects of chemotherapy and its non-selective nature have led researchers to explore combination therapies to enhance efficacy and improve patient outcomes. Parthenolide (PTL) emerges as a promising candidate, being the first small molecule identified for its selective action against leukemic stem cells. This article provides an overview of PTL’s effects and its potential as a complementary treatment for hematological malignancies. A systematic search in PubMed, Scopus, Embase and Web of Science identified relevant studies using keywords and MeSH terms. Peer-reviewed studies examining PTL’s mechanisms and therapeutic potential were included, while non-hematological studies and those lacking rigor were excluded. PTL targets key signaling pathways to combat malignancy, inhibiting NF-κB and signal transducer and STAT3, promoting ROS production, and activating p53. These mechanisms contribute to its effectiveness in treating hematological malignancies. Approaches incorporating PTL or its derivatives show promise in increasing leukemic cell sensitivity to existing therapies and reducing resistance likelihood. Additionally, studies indicate that other drugs can synergistically enhance PTL’s ability to eliminate leukemic cells. In conclusion, PTL represents a promising avenue for improving therapeutic outcomes in hematological malignancies, warranting further investigation into its mechanisms and potential in combination therapies.

Schlagwörter

Stichwörter der Autor:innen

NF-kBhematological malignancyherbal extractleukemiaparthenolide

Autor:innen und Institutionen

  • Department of Hematology and Blood Banking, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Zitieren

APA

Zarei, E., Zarei, A., & Omidkhoda, A. (2025). Parthenolide: pioneering new frontiers in hematological malignancies. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1534686

Vancouver

Zarei E, Zarei A, Omidkhoda A. Parthenolide: pioneering new frontiers in hematological malignancies. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1534686

BibTeX
@article{Zarei2025,
  author = {Zarei, Elmira and Zarei, Ayda and Omidkhoda, Azadeh},
  title = {Parthenolide: pioneering new frontiers in hematological malignancies},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1534686}
}
Kostenlos starten →